ACLX Company Profile and Key Details

ACLX has shown weak momentum, losing -12.01% over the past week and -17.85% over the past quarter, though year-to-date performance is down -16.6%. Short-term trend indicators are mixed aligned (SMA20 -10.11%, SMA50 -21.11%, SMA200 -10.64%). The stock’s 14-day RSI is 30.86 (weak momentum), while the ATR of 4.28 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -32.01% below its high and over 33.64% above its low. Average 10-day trading volume of 1.28 million shares is significantly above the 3-month average of 840.45 thousand, indicating heightened recent market interest.

Arcellx, Inc. has 57.82 million shares outstanding. The public float is 39.70 million shares, elevated short interest at 15.22% of float. This equals 6.45 million shares. The short ratio is 7.65 days. Institutional investors hold 113.57% of the float. Insiders own 13.45%. New Enterprise Associates 15, L.P. holds 6.75 million shares, Novo Holdings A/S has 4.02 million shares and SR ONE CAPITAL MANAGEMENT, LLC has 1.66 million shares. Over the past six months, insider transactions show net selling. They sold 29.29 thousand shares across 9 transactions.

Arcellx, Inc. (NASDAQ:ACLX) closed at $65.18 USD, gaining $1.22 (1.91%) from the previous close of $63.96. The stock is currently mid-range between its 52-week high and low $47.86 and $94.07. With a market capitalization of about $3.61 billion, Arcellx, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.34). Key stats such as the average daily volume over the past year has been around 867.24 thousand shares, in line with its 52-week average. Headquartered in Redwood City, MD, Arcellx, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Rami Elghandour, the company employs approximately 163 people and listed since February 04, 2022. Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases.

Arcellx, Inc. generated EPS of -$3.92 over the past year. Five-year average earnings growth is -31.14%. Wall Street analysts project EPS growth of 4.18% annually over the next five years. The latest quarter delivered EPS of -$0.99. The next quarter is forecast at -$1.06. Next year's EPS is expected at $9.89. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 6 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $133.00 to $88.00. The high target offers 107.94% upside. The low target suggests 37.59% downside. The mean target is $115.56. This offers 80.68% upside. Arcellx, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by 3.13%. The prior quarter beat by -8.74%. Over the last six quarters, Apple has recorded several small beats. These include -5.56% in August 08, 2024.

Arcellx, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $33.43. This means the shares are trading above this model’s fair value.

Our AI price prediction model suggests that Arcellx, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -12.98%, with price expected at $55.66 by January 02, 2026, within a range of $50.86 to $60.67 3-Month Outlook: Projected fall of -24.5%, reaching $48.29 by March 19, 2026, with a range of $46.55 to $49.80. 1-Year Outlook: Projected gain of 29.35%, with price at $82.73 by December 18, 2026, within a range of $78.77 to $86.93.

Arcellx, Inc. (NASDAQ:ACLX) shares are down -16.6% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Arcellx, Inc. trading at a premium to the broader market with a P/E of -19.45. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $74.18, suggesting 15.98% upside. Our AI forecast model points to short-term weakness (-12.98% over two weeks), a medium-term fall (-24.5% over three months), and a longer-term gain (29.35% over one year), with expected trading ranges indicating moderate volatility.

Arcellx, Inc. trades at a P/E ratio of -19.45, slightly below the S&P 500 average, with a price-to-sales ratio of 63.22 and a price-to-book ratio of 9.32 trading at moderately above to book value. The P/FCF stands at -29.23, also below market averages.